MillennialEYE named Kathryn M. Hatch, MD, an “Outstanding female leader in ophthalmology” in their January/February 2017, and published a profile about her career and work. MillennialEYE is an all-digital publication and online community for the future leaders in ophthalmology.
Mass. Eye and Earwas included in Boston Magazine's "Boston Hospitals with Niche Specialties," as the only hospital with a 24/7 eye emergency room in New England. See the full article in Boston Magazine.
ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, has announced that Joan W. Miller, MD, Chair of the Department of Ophthalmology, Harvard Medical School and Chief of Ophthalmology at Massachusetts Eye and Ear and Massachusetts General Hospital, is one of five of the world’s premier retinal disease thought leaders who will serve on its newly formed scientific advisory board (SAB). The goal of
Endre A. Balazs, a pioneer in viscoelastic therapeutics and a leader in hyaluronan and vitreous research, passed away on August 29th at the age of 95. Dr. Balazs had a central role in establishingwhat is now Schepens Eye Research Institute, and was awarded the Institute's
Boston, MA Researchers at Massachusetts Eye and Ear and Schepens Eye Research Institute have reconstructed an ancient virus that is highly effective at delivering gene therapies to the liver, muscle, and retina. This discovery, published July 30 in Cell Reports, could potentially be used to design gene therapies that are not only safer and more potent than therapies currently